Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Stage I Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer|Breast Cancer|HER2-negative Breast Cancer|Germline BRCA1 Gene Mutation|Germline BRCA2 Gene Mutation|Deleterious PALB2 Gene Mutation
Interventions: DRUG: Niraparib|DRUG: Dostarlimab
Sponsor: Dana-Farber Cancer Institute
Collaborators: Translational Breast Cancer Research Consortium|Johns Hopkins University|GlaxoSmithKline